Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - telmisartan, quantity: 40 mg - tablet - excipient ingredients: sodium hydroxide; mannitol; sodium stearylfumarate; meglumine; magnesium stearate; povidone - apo-telmisartan is indicated for:,treatment of hypertension,prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - telmisartan, quantity: 80 mg - tablet - excipient ingredients: sodium stearylfumarate; magnesium stearate; mannitol; meglumine; sodium hydroxide; povidone - apo-telmisartan is indicated for:,treatment of hypertension,prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; meglumine; lactose; magnesium stearate; povidone; lactose monohydrate; crospovidone - telmisartan sandoz is indicated for treatment of hypertension, prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: meglumine; magnesium stearate; lactose; sodium hydroxide; povidone; lactose monohydrate; crospovidone - telmisartan sandoz is indicated for treatment of hypertension, prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage.

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - telmisartan, quantity: 80 mg - tablet, uncoated - excipient ingredients: meglumine; povidone; sodium hydroxide; magnesium stearate; mannitol - telmisartan mylan is indicated for:,? treatment of hypertension,? prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - telmisartan, quantity: 40 mg - tablet, uncoated - excipient ingredients: sodium hydroxide; magnesium stearate; mannitol; povidone; meglumine - telmisartan mylan is indicated for:,? treatment of hypertension,? prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - telmisartan, quantity: 80 mg - tablet - excipient ingredients: sodium hydroxide; mannitol; magnesium stearate; sodium stearylfumarate; povidone; meglumine - telmisartan gh is indicated for:,treatment of hypertension,prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - telmisartan, quantity: 40 mg - tablet - excipient ingredients: mannitol; meglumine; sodium hydroxide; povidone; sodium stearylfumarate; magnesium stearate - telmisartan gh is indicated for:,treatment of hypertension,prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - telmisartan, quantity: 80 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, film coated - excipient ingredients: lactose; povidone; citric acid monohydrate; sodium hydroxide; macrogol poly(vinyl alcohol) grafted polymer; magnesium stearate; meglumine; colloidal anhydrous silica; lactose monohydrate; crospovidone - telmisartan/hct sandoz? is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

United States - English - NLM (National Library of Medicine)

alembic pharmaceuticals limited - telmisartan (unii: u5syw473rq) (telmisartan - unii:u5syw473rq), amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288) - telmisartan 40 mg - telmisartan and amlodipine tablets   are indicated for the treatment of hypertension, alone or with other antihypertensive agents to lower blood pressure. lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. these benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including angiotensin ii receptor blockers and dihydropyridine calcium channel blockers. there are no controlled trials demonstrating risk reduction with telmisartan and amlodipine tablets. control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. many patients will require more than one drug to achieve blood pressure goals. for specific advice on goals and management, see published guidelines, such as those of the national high b